Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium

John D. HainsworthSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Anthony A. MeluchSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Cassie M. LaneSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

David R. SpigelSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Howard A. Burris IIISarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Jitendra G. GandhiSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Edward J. CraneSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

Michael A. StipanovSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

F. Anthony GrecoSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.

show all

ABSTRACT

Patients with metastatic prostate cancer resistant to hormones and docetaxel were treated with vinflunine (320 mg/m² every 21 days), a new vinca alkaloid with improved preclinical activity. Only 1 of 36 patients (3%) had partial response; the median progression-free survival (PFS) was 2.1 months. Treatment was well tolerated, with myelosuppression as the only frequent toxicity. Vinflunine has a low level of activity in the treatment of refractory metastatic prostate cancer, and should not be further developed for this indication.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium

Information for

Open access

Opportunities

Help and information

Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature